Protagonist Therapeutics, Inc(PTGX)Stock Analysis

PTGX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Protagonist Therapeutics, Inc (PTGX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PTGX at 24.8/100 on a 32-signal composite quality model, placing it at rank #2,572 of 2,879 stocks — the bottom half of the AI-ranked universe. PTGX scores in the top quartile across free cash flow (91.8). Areas of concern include revenue growth (2.0) and profitability (7.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Protagonist Therapeutics, Inc reports quarterly revenue of $56.4M, net income of $3.8M, free cash flow of $-49.2M. Top institutional holders of PTGX by reported 13-F value include BlackRock,, FARALLON CAPITAL MANAGEMENT, UBS Group AG, based on the most recent SEC filings. PTGX trades on the Nasdaq exchange and files with the SEC under CIK 1377121. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PTGX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Protagonist Therapeutics, Inc directly from SEC EDGAR. Protagonist Therapeutics, Inc's 13F Pro composite quality score has ranged between 8 and 53 since 2026, currently 24.8 — an improving long-term trajectory across 36 quarterly and live scoring snapshots.